Tesamorelin + Ipamorelin
What is Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin: Combination of tesamorelin (GHRH analogue, FDA-approved Egrifta for HIV visceral fat) and ipamorelin (selective ghrelin-receptor GH secretagogue, not FDA-approved). The sources cited here most often discuss it for: Synergistic GH release, theoretical; Belly fat, via tesamorelin; Deeper sleep, anecdotal. Evidence label: Unstudied.
- Type
- Blend
- Family
- Growth Hormone Axis
- Evidence label
- Unstudied (1 of 5)
- Regulatory status
- Dr. Axe's A-Z guide lists tesamorelin as FDA-approved for a specific HIV-related belly fat condition, while it lists ipamorelin, paired with CJC-1295, as research only and not FDA-approved.
- Goals discussed
- Hormones & Fertility, Fat Loss & Metabolism, Heart, Liver & Kidney, Sleep
- Also called
- Egrifta WR, Egrifta SV, tesamorelin acetate, Ipamorelin acetate, Tesa, IPA, Tesamorelin/Ipamorelin
- Last reviewed
- 2026-10-11
- Combination of tesamorelin (GHRH analogue, FDA-approved Egrifta for HIV visceral fat) and ipamorelin (selective ghrelin-receptor GH secretagogue, not FDA-approved); intent is synergistic endogenous GH/IGF-1 release via two receptor pathways; the blend itself has never been studied.12
Tesamorelin (Egrifta) is a GHRH analog distinct from sermorelin and CJC-1295; ipamorelin is more often paired with CJC-1295, and the tesamorelin pairing is a separate, unstudied combination.
Regulatory status Dr. Axe's A-Z guide lists tesamorelin as FDA-approved for a specific HIV-related belly fat condition, while it lists ipamorelin, paired with CJC-1295, as research only and not FDA-approved. 3
A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.
FDA safety summary for ipamorelin acetate, still in 503B category 2; the events involved intravenous use for gastric motility, and FDA says it lacks safety data for other injection routes.
What is Tesamorelin + Ipamorelin researched for?
The three outcomes most discussed for Tesamorelin + Ipamorelin in the sources below, as those sources report them. humanpeptides.fyi makes no claims of its own: a listed benefit can be unproven or can have failed in trials, and the label on each line says which.
What do researchers and users say about Tesamorelin + Ipamorelin?
The effects of prolonged elevations in IGF-1 levels are unknown.
Warning in the US label for tesamorelin, which raises growth hormone and IGF-1.
Sleeps been phenomenal, and my belly fat is being assassinated.
Forum reply from a user of a tesamorelin and ipamorelin blend; others in the thread report water retention and carpal tunnel symptoms.
What side effects of Tesamorelin + Ipamorelin are reported?
- Water retention, bloating, injection-site pain, occasional histamine-like reactionsanecdotal8
- Tesamorelin label risks: arthralgia, edema, carpal tunnel, glucose intolerance, malignancy caution1
- Hypersensitivity reactions such as itching, redness, flushing, hives and rash occurred in 4% of tesamorelin-treated patients in trials.FDA label12
- About half of patients in tesamorelin trials developed anti-tesamorelin antibodies.FDA label12
- Growth hormone at pharmacologic levels has been linked to increased mortality in acutely critically ill patients, and the tesamorelin label advises considering discontinuation in that setting.FDA label12
- Tesamorelin is contraindicated in pregnancy because it could cause fetal harm.FDA label12
- Possible immunogenicity from aggregation or impurities in compounded ipamorelin; serious adverse events including death were reported with intravenous ipamorelin.FDA assessment11
What do peptide guides say about Tesamorelin + Ipamorelin?
- Dr. Axe Dr. Axe's library notes tesamorelin is approved only for HIV-associated abdominal fat, not general weight loss, with contraindications including active malignancy and pregnancy, and glucose and IGF-1 monitoring advised. 13
- Dr. Axe Dr. Axe points out that the World Anti-Doping Agency list includes growth hormone-releasing peptides such as ipamorelin and tesamorelin, so tested athletes risk sanctions. 3
- PepEdHub PepEdHub says tesamorelin is often combined with ipamorelin to boost GH release, and advises monitoring IGF-1, glucose and HbA1c during therapy. 14
- PepEdHub PepEdHub describes ipamorelin as a selective ghrelin-receptor agonist with little effect on cortisol or prolactin, listing water retention, tingling in the extremities and increased hunger as possible effects. 15
- Seek Peptides Seek Peptides presents ipamorelin plus tesamorelin as a visceral-fat pairing, with ipamorelin adding complementary GH stimulation, offered as a rationale rather than a tested protocol. 16
What does the research say, system by system?
How strong is the evidence for Tesamorelin + Ipamorelin?
Blend unstudied; tesamorelin has strong human data, ipamorelin mostly animal; GHRH+GHRP synergy shown in older human physiology studies; blend benefits anecdotal
No direct studies of this product or blend. Anecdote and component data only. How tiers work
Questions about Tesamorelin + Ipamorelin
What is Tesamorelin + Ipamorelin?
Combination of tesamorelin (GHRH analogue, FDA-approved Egrifta for HIV visceral fat) and ipamorelin (selective ghrelin-receptor GH secretagogue, not FDA-approved). Tesamorelin (Egrifta) is a GHRH analog distinct from sermorelin and CJC-1295; ipamorelin is more often paired with CJC-1295, and the tesamorelin pairing is a separate, unstudied combination.
Is Tesamorelin + Ipamorelin FDA-approved?
Dr. Axe's A-Z guide lists tesamorelin as FDA-approved for a specific HIV-related belly fat condition, while it lists ipamorelin, paired with CJC-1295, as research only and not FDA-approved.
What is Tesamorelin + Ipamorelin researched for?
The sources cited on this page most often discuss three outcomes: Synergistic GH release, theoretical; Belly fat, via tesamorelin; Deeper sleep, anecdotal. Each line above shows what the source reports and how strong that evidence is.
What side effects of Tesamorelin + Ipamorelin are reported?
Reported in the cited sources: Water retention, bloating, injection-site pain, occasional histamine-like reactions; Tesamorelin label risks: arthralgia, edema, carpal tunnel, glucose intolerance, malignancy caution; Hypersensitivity reactions such as itching, redness, flushing, hives and rash occurred in 4% of tesamorelin-treated patients in trials. The list is not complete, and few listed risks does not mean a compound is safe.
How strong is the evidence for Tesamorelin + Ipamorelin?
Evidence label: Unstudied. Blend unstudied; tesamorelin has strong human data, ipamorelin mostly animal; GHRH+GHRP synergy shown in older human physiology studies; blend benefits anecdotal.
What else is Tesamorelin + Ipamorelin called?
Names used for it include Egrifta WR, Egrifta SV, tesamorelin acetate, Ipamorelin acetate, Tesa, IPA, Tesamorelin/Ipamorelin.
Does humanpeptides.fyi recommend Tesamorelin + Ipamorelin?
No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician.